tbuckley/cabot-search huggingface dataset:
Large socio-economic, geographic and demographic disparities exist in exposure to school closures
Authors: Zachary Parolin, Emma K. Lee
Journal: Nature Human Behaviour (2021)

The coronovirus disease 2019 (COVID-19) pandemic has prompted many school districts to turn to distance or at-home learning. Studies are emerging on the negative effects of distance learning on educational performance, but less is known about the socio-economic, geographic and demographic characteristics of students exposed to distance learning. We introduce a U.S. School Closure and Distance Learning Database that tracks in-person visits across more than 100,000 schools throughout 2020. The database, which we make publicly accessible and update monthly, describes year-over-year change in in-person visits to each school throughout 2020 to estimate whether the school is engaged in distance learning. Our findings reveal that school closures from September to December 2020 were more common in schools with lower third-grade math scores and higher shares of students from racial/ethnic minorities, who experience homelessness, have limited English proficiency and are eligible for free/reduced-price school lunches. The findings portend rising inequalities in learning outcomes.
FP04.01 Heart Dose is a Dosimetric Predictor of Overall Survival in Patients with NSCLC Undergoing Post-Operative Radiation Therapy
Authors: A. Shepherd, A. Yu, M. Al-Sadawi, A. Peleg, M. Iocolano, J. Leeman, B. Imber, A. Wild, M. Offin, J. Chaft, J. Huang, A. Rimner, A. Wu, D. Gelblum, N. Shaverdian, D. Gomez, C. Simone Ii, E. Yorke, A. Jackson
Journal: Journal of Thoracic Oncology (2021)
Perceived Usefulness and Recall of Sunscreen Label Information by Consumers
Authors: Calvin P. Tribby, Anne K. Julian, Frank M. Perna
Journal: JAMA Dermatology (2021)

<h3>Importance</h3> In February 2019, the US Food and Drug Administration issued a proposed rule (84 FR 6204), an amendment to the Sunscreen Innovation Act of 2014, that would require listing active ingredients on the principal display panel of sunscreens to allow consumers to "more readily compare products and either select or avoid a given product accordingly." <h3>Objective</h3> To understand consumers' perceived importance of active ingredients in sunscreen and their ability to recall these ingredients when comparing, avoiding, or selecting sunscreen products. <h3>Design, Setting, and Participants</h3> In this qualitative study, participants were recruited from Fors Marsh Group and User Works, Inc consumer panels and interviewed in person in November and December 2019. Eligible participants were 18 years or older, reported sunscreen use in the past 12 months, and were residents of the Washington, DC, area. After viewing 2 mock sunscreen labels (1 that meets current US Food and Drug Administration requirements and 1 designed to meet proposed requirements), participants were asked questions to assess their perceived importance of active ingredients in sunscreen products, whether they could recall any of the active ingredients on the labels, and whether they typically looked for active ingredients on a sunscreen label. <h3>Main Outcomes and Measures</h3> The main outcomes were the sunscreen label information used by participants to select a sunscreen and their ability to recall the active ingredients after viewing 2 mock sunscreen labels. <h3>Results</h3> The mean (SD) age of the 47 participants was 42.8 (13.6) years, 32 (68%) were women, and 40 (85%) had a bachelor's or graduate degree. Of the total, 13 (28%) participants stated that sunscreen ingredients influenced their sunscreen selection, but only 5 (11%) said it was the most important information. Instead, 34 (72%) participants stated that the sun protection factor rating was the most important information. After viewing the mock sunscreen labels, only 5 (11%) participants recalled any of the active ingredients, although 10 (21%) reported typically looking at active ingredients when choosing a sunscreen. <h3>Conclusions and Relevance</h3> This qualitative study investigated the US Food and Drug Administration's proposed new rule requiring that active ingredients be listed on the front of sunscreen labels to facilitate product comparison for consumers. However, active ingredients were not reported to be a primary reason for consumers' sunscreen selection. Recall of active ingredients was low, and few consumers reported typically looking at the active ingredients, which were more commonly used to avoid ingredients rather than to select a sunscreen. Therefore, listing active ingredients on the front label alone may not have the intended usefulness for consumers.
Abstract 15359: Impact of Catheter Ablation in Atrial Fibrillation Patients With Cardiomyopathy
Authors: Akihiro Sunaga, Hitoshi Minamiguchi, Kentaro Ozu, Tomoaki Nakano, Syuzo Konishi, Tomohito Otani, Shungo Hikoso, Masaharu Masuda, Toshiaki Mano, Yasushi Sakata
Journal: Circulation (2018)

Introduction: Although catheter ablation (CA) improves the outcome of the atrial fibrillation (AF) patients with low left ventricular ejection fraction (LVEF), it is still unknown whether the outco...
Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes
Authors: Grégory Ehx, Jean-David Larouche, Chantal Durette, Jean-Philippe Laverdure, Leslie Hesnard, Krystel Vincent, Marie-Pierre Hardy, Catherine Thériault, Caroline Rulleau, Joël Lanoix, Eric Bonneil, Albert Feghaly, Anca Apavaloaei, Nandita Noronha, Céline M. Laumont, Jean-Sébastien Delisle, Luca Vago, Josée Hébert, Guy Sauvageau, Sébastien Lemieux, Pierre Thibault, Claude Perreault
Journal: Immunity (2021)
ACL reconstruction for all is not cost-effective after acute ACL rupture
Authors: Vincent Eggerding, Max Reijman, Duncan Edward Meuffels, Eline van Es, Ewoud van Arkel, Igor van den Brand, Joost van Linge, Jacco Zijl, Sita MA Bierma-Zeinstra, Marc Koopmanschap
Journal: British Journal of Sports Medicine (2021)

Objectives To conduct a cost-utility analysis for two commonly used treatment strategies for patients after ACL rupture; early ACL reconstruction (index) versus rehabilitation plus an optional reconstruction in case of persistent instability (comparator). Methods Patients aged between 18 and 65 years of age with a recent ACL rupture (&lt;2 months) were randomised between either an early ACL reconstruction (index) or a rehabilitation plus an optional reconstruction in case of persistent instability (comparator) after 3 months of rehabilitation. A cost-utility analysis was performed to compare both treatments over a 2-year follow-up. Cost-effectiveness was calculated as incremental costs per quality-adjusted life year (QALY) gained, using two perspectives: the healthcare system perspective and societal perspective. The uncertainty for costs and health effects was assessed by means of non-parametric bootstrapping. Results A total of 167 patients were included in the study, of which 85 were randomised to the early ACL reconstruction (index) group and 82 to the rehabilitation and optional reconstruction group (comparator). From the healthcare perspective it takes 48 460 € and from a societal perspective 78 179 €, to gain a QALY when performing early surgery compared with rehabilitation plus an optional reconstruction. This is unlikely to be cost-effective. Conclusion Routine early ACL reconstruction (index) is not considered cost-effective as compared with rehabilitation plus optional reconstruction for a standard ACL population (comparator) given the maximum willingness to pay of 20 000 €/QALY. Early recognition of the patients that have better outcome of early ACL reconstruction might make rehabilitation and optional reconstruction even more cost-effective.
Risk for Non–AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy
Authors: Frédérique Chammartin, Sara Lodi, Roger Logan, Lene Ryom, Amanda Mocroft, Ole Kirk, Antonella d’Arminio Monforte, Peter Reiss, Andrew Phillips, Wafaa El-Sadr, Camilla I. Hatleberg, Christian Pradier, Fabrice Bonnet, Matthew Law, Stéphane De Wit, Caroline Sabin, Jens D. Lundgren, Heiner C. Bucher
Journal: Annals of Internal Medicine (2021)

Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 × 109 cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear.To estimate the long-term risk difference for cancer with the immediate ART strategy.Multinational prospective cohort study.The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included HIV-positive persons from Europe, Australia, and the United States.8318 HIV-positive persons with at least 1 measurement each of CD4 cell count and viral load while ART-naive (study period, 2006 to 2016).The parametric g-formula was used, with adjustment for baseline and time-dependent confounders (CD4 cell count and viral load), to assess the 10-year risk for non-AIDS-defining and AIDS-defining cancer of immediate versus deferred (at CD4 counts <350 and <500 × 109 cells/L) ART initiation strategies.During 64 021 person-years of follow-up, 231 cases of non-AIDS-defining cancer and 272 of AIDS-defining cancer occurred among HIV-positive persons with a median age of 36 years (interquartile range, 29 to 43 years). With immediate ART, the 10-year risk for non-AIDS-defining cancer was 2.97% (95% CI, 2.37% to 3.50%) and that for AIDS-defining cancer was 2.50% (CI, 2.37% to 3.38%). Compared with immediate ART initiation, the 10-year absolute risk differences when deferring ART to CD4 counts less than 500 × 109 cells/L and less than 350 × 109 cells/L were 0.12 percentage point (CI, -0.01 to 0.26 percentage point) and 0.29 percentage point (CI, -0.03 to 0.73 percentage point), respectively, for non-AIDS-defining cancer and 0.32 percentage point (CI, 0.21 to 0.44 percentage point) and 1.00 percentage point (CI, 0.67 to 1.44 percentage points), respectively, for AIDS-defining cancer.Potential residual confounding due to observational study design.In this young cohort, effects of immediate ART on 10-year risk for cancer were small, and further supportive data are needed for non-AIDS-defining cancer.Highly Active Antiretroviral Therapy Oversight Committee.
P09.25 Role of Immune Checkpoint Inhibitors (ICPi) in KRAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
Authors: M. Peravali, C. Gomes-Lima, E. Tefera, M. Baker, M. Sherchan, S. Farid, K. Burman, F. Constantinescu, I. Veytsman
Journal: Journal of Thoracic Oncology (2021)
Insights on Intensive Vs Nonintensive Prerandomization Systolic Blood Pressure Reduction—Reply
Authors: Adnan I. Qureshi, Wei Huang, Iryna Lobanova
Journal: JAMA Neurology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
OA04.06 Neratinib in Pretreated EGFR Exon 18-Mutant Non-Small Cell Lung Cancer (NSCLC): Initial Findings From the SUMMIT Basket Trial
Authors: V. Boni, C. Dooms, B. Haley, S. Viteri, A. Mahipal, J. Suga, L. Eli, A. Lalani, R. Bryce, F. Xu, N. Shah, F. Kabbinavar, J. Goldman
Journal: Journal of Thoracic Oncology (2021)
Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19
Authors: Hanny Al-Samkari
Journal: JAMA (2021)

INSPIRATION Investigators; Saeideh Mazloomzadeh; Shiva Khaleghparast; Behshid Ghadrdoost; Mostafa Mousavizadeh; Mohammad Reza Baay; Feridoun Noohi; Hamidreza Sharifnia; Arezoo Ahmadi; Sasan Tavan; Nasser Malekpour Alamdari; Mohammad Fathi; Mahshid Soleimanzadeh; Mostafa Mostafa; Navid Davoody; Maryam Zarinsadaf; Sara Tayyebi; Fahimeh Farrokhzadeh; Faeze Nezamabadi; Esmaeil Soomari; Parham Sadeghipour, MD; Azita H. Talasaz, PharmD; Farid Rashidi, MD; Babak Sharif-Kashani, MD; Mohammad Taghi Beigmohammadi, MD; Mohsen Farrokhpour, MD; Seyed Hashem Sezavar, MD; Pooya Payandemehr, MD; Ali Dabbagh, MD; Keivan Gohari Moghadam, MD; Sepehr Jamalkhani, MD ('23); Hossein Khalili, PharmD; Mahdi Yadollahzadeh, MD; Taghi Riahi, MD; Parisa Rezaeifar, MD; Ouria Tahamtan, MD; Samira Matin, MD; Atefeh Abedini, MD; Somayeh Lookzadeh, MD; Hamid Rahmani, PharmD; Elnaz Zoghi, PharmD; Keyhan Mohammadi, PharmD; Pardis Sadeghipour, MD; Homa Abri, MD; Sanaz Tabrizi, MD; Seyed Masoud Mousavian, MD; Shaghayegh Shahmirzaei, MD; Hooman Bakhshandeh, MD, PhD; Ahmad Amin, MD; Farnaz Rafiee, MD; Elahe Baghizadeh, MD; Bahram Mohebbi, MD; Seyed Ehsan Parhizgar, MD; Rasoul Aliannejad, MD; Vahid Eslami, MD; Alireza Kashefizadeh, MD; Hessam Kakavand, PharmD; Seyed Hossein Hosseini, PharmD; Shadi Shafaghi, MD; Samrand Fattah Ghazi, MD; Atabak Najafi, MD; David Jimenez, MD, PhD; Aakriti Gupta, MD, MS; Mahesh V. Madhavan, MD; Sanjum S. Sethi, MD, MPH; Sahil A. Parikh, MD; Manuel Monreal, MD; Naser Hadavand, PharmD; Alireza Hajighasemi, PharmD; Majid Maleki, MD; Saeed Sadeghian, MD; Gregory Piazza, MD, MS; Ajay J. Kirtane, MD, SM; Benjamin W. Van Tassell, PharmD; Paul P. Dobesh, PharmD; Gregg W. Stone, MD; Gregory Y. H. Lip, MD; Harlan M. Krumholz, MD, SM; Samuel Z. Goldhaber, MD; Behnood Bikdeli, MD, MS
P21.10 Real-World Treatment Patterns in Chinese Stage III NSCLC Patients - A Prospective, Non-Interventional Study (MOOREA trial)
Authors: J. Yu, L. Xing, G. Cheng, L. Chen, L. Dong, X. Fu, Y. Guo, Z. Han, D. Jiang, J. Li, Y. Lin, A. Liu, J. Liu, J. Liu, Y. Liu, D. Lv, C. Ma, Y. Ren, S. Wang, Y. Wang, C. Xiao, S. Yan, F. Yang, W. Yang, A. Zang, X. Zhang, Y. Zhang, R. Zhao, J. Zhou
Journal: Journal of Thoracic Oncology (2021)
Environment And Genetics in Lung cancer Etiology (EAGLE): A novel population-based case-control study of lung cancer.
Authors: Melissa Rotunno, Angela Pesatori, Andrew Bergen, Peggy Tucker, Sholom Wacholder, Alisa Goldstein, Jay Lubin, Lynn Goldin, Michael Alavanja, Amy Subar, Glen Morgan, Dario Consonni, PierAlberto Bertazzi, Neil Caporaso, Maria Teresa Landi
Journal: Cancer Research (2007)

91  EAGLE is a large population-based case-control study designed to investigate the genetic and environmental determinants of lung cancer, smoking persistence, survival and therapy efficacy through combined analysis of genetic, environmental, clinical, and behavioral data. Field activities have recently concluded. Lung cancer cases were enrolled from 13 hospitals within the Lombardy region of Italy. The healthy controls were randomly selected from the same residential area of the lung cancer cases. The participation rate was high, 85% in cases and 73% in controls. The study includes 2,117 incident lung cancer cases, both males (78%) and females (22%) of Italian nationality, ages 35 to 79 years old, with verified lung cancer of any histological type, and 2,120 healthy population-based controls matched to cases by age, gender, and residence. Adenocarcinoma was the most frequent histology subtype overall (38%) and in never smokers (62%), and differed by sex (50% in females and 35% in males, overall). Interestingly, bronchoalveolar carcinoma showed the highest frequency in former smokers (53%) compared to current smokers (26%) and never smokers (21%). In contrast, all other histological subtypes, particularly small cell and large cell, had higher frequency in current smokers. Stage I tumors were more frequent in former (49%) than current (43%) smokers, while later stages were more frequent in current smokers. We collected extensive epidemiological, behavioral, and clinical data, as well as multiple biospecimens from virtually all lung cancer cases and controls. Tissue specimens, including multiple fresh “normal” lung tissue and tumor samples, were collected from surgical cases. As expected, tobacco smoking was associated with lung cancer (OR=5.0, 95% CI=4.0-6.1, and OR=11.0, 95% CI=8.8-13.6, in former and current smokers, respectively, when compared with never smokers and adjusting for matching variables). Initial analyses show that family history of cancer in first-degree relatives (OR=1.3, 95% CI=1.1-1.4), and low education level (p=0.003, test for trend, from elementary to post-graduate education) are risk factors for lung cancer in EAGLE, even after adjustment for smoking and matching variables. We are exploring the role of passive smoking, sex, occupation, diet, willingness to participate in the study, and other factors in the association with lung cancer, and behavioral data (Fagerstrom index, measures of depression, anxiety, and personality) in relation to smoking persistence. Extensive genetic investigations are also underway. This study will help answer many questions related to lung cancer etiology.
Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders
Authors: Brittany N. Weber, Emma Stevens, Lourdes M. Perez-Chada, Jenifer M. Brown, Sanjay Divakaran, Camden Bay, Courtney Bibbo, Jon Hainer, Sharmila Dorbala, Ron Blankstein, Viviany R. Taqueti, Joseph F. Merola, Elena Massarotti, Karen Costenbader, Katherine Liao, Marcelo F. Di Carli
Journal: JACC. Cardiovascular imaging (2021)
A Comprehensive Phylogenetic Analysis of the Serpin Superfamily
Authors: Matthew A Spence, Matthew D Mortimer, Ashley M Buckle, Bui Quang Minh, Colin J Jackson
Journal: Molecular Biology and Evolution (2021)

Serine protease inhibitors (serpins) are found in all kingdoms of life and play essential roles in multiple physiological processes. Owing to the diversity of the superfamily, phylogenetic analysis is challenging and prokaryotic serpins have been speculated to have been acquired from Metazoa through horizontal gene transfer due to their unexpectedly high homology. Here, we have leveraged a structural alignment of diverse serpins to generate a comprehensive 6,000-sequence phylogeny that encompasses serpins from all kingdoms of life. We show that in addition to a central "hub" of highly conserved serpins, there has been extensive diversification of the superfamily into many novel functional clades. Our analysis indicates that the hub proteins are ancient and are similar because of convergent evolution, rather than the alternative hypothesis of horizontal gene transfer. This work clarifies longstanding questions in the evolution of serpins and provides new directions for research in the field of serpin biology.
A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer
Authors: Phillip L. Palmbos, Stephanie Daignault-Newton, Scott A. Tomlins, Neeraj Agarwal, Przemyslaw Twardowski, Alicia K. Morgans, Wm. Kevin Kelly, Vivek K. Arora, Emmanuel S. Antonarakis, Javed Siddiqui, Jon A. Jacobson, Matthew S. Davenport, Dan R. Robinson, Arul M. Chinnaiyan, Karen E. Knudsen, Maha Hussain
Journal: Clinical Cancer Research (2021)

Abstract Purpose: Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, blocks proliferation in a RB and cyclin D–dependent manner in preclinical prostate cancer models. We hypothesized that cotargeting androgen receptor and cell cycle with palbociclib would improve outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Patients and Methods: A total of 60 patients with RB-intact mHSPC were randomized (1:2) to Arm 1: androgen deprivation (AD) or Arm 2: AD + palbociclib. Primary endpoint was PSA response rate (RR) after 28 weeks of therapy. Secondary endpoints included safety, PSA, and clinical progression-free survival (PFS), as well as PSA and radiographic RR. Tumors underwent exome sequencing when available. Circulating tumor cells (CTC) were enumerated at various timepoints. Results: A total of 72 patients with mHSPC underwent metastatic disease biopsy and 64 had adequate tissue for RB assessment. A total of 62 of 64 (97%) retained RB expression. A total of 60 patients initiated therapy (Arm 1: 20; Arm 2: 40). Neutropenia was the most common grade 3/4 adverse event in Arm 2. Eighty percent of patients (Arm 1: 16/20, Arm 2: 32/40; P = 0.87) met primary PSA endpoint ≤4 ng/mL at 28 weeks. PSA undetectable rate at 28 weeks was 50% and 43% in Arms 1 and 2, respectively (P = 0.5). Radiographic RR was 89% in both arms. Twelve-month biochemical PFS was 69% and 74% in Arms 1 and 2, respectively (P = 0.72). TP53 and PIK3 pathway mutations, 8q gains, and pretreatment CTCs were associated with reduced PSA PFS. Conclusions: Palbociclib did not impact outcome in RB-intact mHSPC. Pretreatment CTC, TP53 and PIK3 pathway mutations, and 8q gain were associated with poor outcome.
P75.04 Advanced Lung Cancer Inflammation Index (ALI), Neutrophil-to-Lymphocyte Ratio (NLR), and PD-(L)1 Inhibitor Efficacy in NSCLC
Authors: G. Mountzios, E. Samantas, K. Senghas, E. Zervas, J. Krisam, K. Samitas, F. Bozorgmehr, J. Kuon, S. Agelaki, S. Baka, I. Athanasiadis, L. Gaissmaier, M. Elshiaty, L. Daniello, A. Christopoulou, G. Pentheroudakis, E. Lianos, H. Linardou, K. Kriegsmann, P. Kosmidis, R. El Shafie, M. Kriegsmann, A. Psyrri, C. Andreadis, E. Fountzilas, C. Heussel, F. Herth, H. Winter, C. Emmanouilidis, G. Oikonomopoulos, M. Meister, T. Muley, H. Bischoff, Z. Saridaki, E. Razis, E. Perdikouri, A. Stenzinger, I. Boukovinas, M. Reck, K. Syrigos, M. Thomas, P. Christopoulos
Journal: Journal of Thoracic Oncology (2021)
Abstract 15033: Trends in Incidence and Mortality From Atrial Fibrillation/Flutter Across the United States: 1990 to 2017
Authors: Augustin DeLago, Justin D Salciccioli, Dominic C Marshall, Binu Philips
Journal: Circulation (2019)

Introduction: Atrial fibrillation is the most common clinically significant arrhythmia in older adults with an increasing disease burden due to an aging population. However, up-to-date trends in di...
Iain Hayden Arthurson
Authors: Ken Stewart
Journal: BMJ (2021)

After graduating, Iain Hayden Arthurson (“Hayden”) went south to the West Middlesex Hospital for his house jobs and did six months in anaesthetics, obtaining his DA. He then spent six months in Canada as a GP locum, perhaps considering emigration. He wasn’t impressed, returned to Scotland, and entered general practice. He became a partner at the Ladywell Medical Centre East in Corstorphine, Edinburgh. The job …
P78.15 Real-World Prognostic Model of Overall Survival in Patients With Advanced NSCLC Receiving Anti-PD1/PD-L1 as 2L Monotherapy
Authors: C. Julian, R. Machado, S. Girish, P. Chanu, D. Heinzmann, C. Harbron, A. Gershon, S. Pfeiffer, W. Zou, V. Quarmby, Q. Zhang, Y. Chen
Journal: Journal of Thoracic Oncology (2021)